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In this issue of Neuron, Fo¨ldy et al. (2013) report that endocannabinoid-mediated signaling at inhibitory
synapses is dysregulated in mouse models of autism-associated Neuroligin-3 mutations. These findings
carry implications regarding the pathophysiology of autism spectrum disorders and the development of
treatment strategies.The correct wiring of the brain during
development is an extremely complex
biological process, during which a stag-
gering number of synapses with often
very diverse characteristics have to be
formed and maintained in a precise
and delicate balance. Not surprisingly,
therefore, numerous neurodevelopmental
and psychiatric diseases appear to be
disorders of aberrant synaptogenesis
and synapse function, or ‘‘synaptopa-
thies.’’ Particularly in the context of autism
spectrum disorders (ASDs), an ever-
growing number of mutations in genes
encoding synaptic proteins have been
identified in affected individuals (Murdoch
and State, 2013), and major research ef-
forts are currently focusing on strategies
to transform this knowledge base into
viable treatment strategies.
However, the corresponding chal-
lenges are substantial. For example, very
little is known about the role of ASD-related synaptic proteins in vivo, e.g., in
neuronal circuits that control autism-
relevant behavior. Second, many known
ASD-related proteins are structural pro-
teins with adhesion or scaffold functions
and therefore poor targets for pharmaco-
logical intervention with small molecule
drugs. Third, many ASD-related muta-
tions lead to a loss of the corresponding
protein so that no target for pharmaco-
logical intervention remains. Finally, each
individual ASD-related mutation is rare,
with the vast majority accounting for less
than 1% of affected individuals each. In
view of these difficulties, the focus in the
field of ASD biology has shifted toward
the identification of cellular protein-pro-
tein interactions or signaling pathways
that are common to the various ASD-
related proteins and therefore expected
to be perturbed by a wide range of
ASD-related mutations—with the hope
that such pathways may represent morepromising treatment targets than the
ASD-linked proteins discovered so far.
One of the synaptic proteins associated
with ASDs is Neuroligin-3 (NLGN3), a
member of the Neuroligin family of post-
synaptic cell adhesion molecules that
interact with presynaptic Neurexins to
control synapse development and func-
tion. Two distinct mutations in NLGN3
have been linked to ASDs, a point muta-
tion resulting in an R451C substitution in
the Neurexin-binding domain (Jamain
et al., 2003) and a deletion of the NLGN3
gene (Sanders et al., 2011). Studies
on the respective mouse models, a
Nlgn3R451C knockin (KI) and a Nlgn3
knockout (KO), showed that both muta-
tions cause ASD-related behavioral phe-
notypes (Radyushkin et al., 2009; Tabuchi
et al., 2007) but have strikingly different
effects on synapse and network function,
with the Nlgn3R451C mutation resulting
in a gain-of-function phenotype that is
Figure 1. Potential Role of Nlgn3 at Perisomatic Inhibitory Synapses on CA1 Pyramidal
Neurons
PV and CCK basket cells form perisomatic inhibitory synapses onto pyramidal neurons. Boxed inserts
summarize the data reported by Fo¨ldy et al. (2013). Expanded views show a model of how Nlgn3 may
affect PV basket cell synapses (upper left) and CCK basket cell synapses (lower right) based on these
findings. It should be noted that the presence of Nlgn3 at these synapses has not been investigated
and is inferred from the data. Abbreviations: Nlgn3, Neuroligin-3; PV, parvalbumin; CCK, cholecystokinin;
SV, synaptic vesicle; MOR, m-opioid receptor; M2, M2 muscarinic acetylcholine receptor; CB1R, canna-
binoid receptor type 1.
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Previewsunrelated to the loss of function caused
by the Nlgn3 deletion (Baudouin et al.,
2012; Etherton et al., 2011; Tabuchi
et al., 2007).In a new study published in the current
issue of Neuron, Fo¨ldy and colleagues
searched for common phenotypic
changes in Nlgn3R451C KI and Nlgn3 KONeuromice that might explain the similar ASD-
related behavioral changes in these
mouse lines and may therefore be partic-
ularly relevant to ASDs (Fo¨ldy et al., 2013).
To this end, the authors investigated
GABAergic synaptic transmission in
the hippocampus of Nlgn3R451C KI and
Nlgn3 KO mice, focusing on the synaptic
connections between inhibitory basket
cells and pyramidal neurons, which are
known to play a fundamental role in the
generation of the network oscillations
that underlie a number of cognitive func-
tions controlled by the hippocampus
(Lisman and Buzsa´ki, 2008). Two types
of basket cells are particularly relevant
for this process, parvalbumin-containing
(PV) and cholecystokinin-containing
(CCK) basket cells, and Fo¨ldy et al.
(2013) employed paired whole-cell re-
cordings to monitor perisomatic synap-
ses formed by each of these inhibitory
cell types onto postsynaptic pyramidal
neurons (Figure 1).
The authors found that synaptic trans-
mission is substantially impaired at
PV basket cell synapses in Nlgn3R451C
KI mice, with IPSC amplitudes reduced
by 70%. No such alterations were
observed in the Nlgn3 KOs, consistent
with the previously published notion that
the R451C substitution exerts its influence
by a gain-of-function mechanism. Unex-
pectedly in view of the postsynaptic local-
ization of Nlgn3, this decrease in IPSC
amplitude appears to be of presynaptic
origin anddue toa reduction inpresynaptic
transmitter release probability. In contrast,
no evidence for changes in postsynaptic
GABA receptor number or composition,
in the total number of synapses, in quantal
size or the number of release sites, or in the
activation of presynaptic receptors that
modulate release probability was ob-
served. The authors conclude that the
Nlgn3R451C KI affects the presynaptic
transmitter release machinery at PV
basket cell synapses through gain-of-
function alterations in transsynaptic sig-
naling, although the precise mechanism
has yet to be elucidated.
While these experiments provided valu-
able new insights into the mechanisms
by which the R451C substitution might
affect Nlgn3 function, they failed to
uncover common phenotypic features
of the two Nlgn3 mutants that might be
related topathwaysofparticular relevancen 78, May 8, 2013 ª2013 Elsevier Inc. 409
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et al. (2013) next investigated transmission
at CCK basket cell synapses. Unexpect-
edly, the authors found that the
Nlgn3R451C KI phenotype at these CCK
basket cell synapses was diametrically
opposite to the one found at PV basket
cell synapses, with IPSC amplitudes
substantially increased rather than
decreased. Aswith the PV basket cell syn-
apses, this phenotypic change is again
likely the result of an alteration in presyn-
aptic GABA release probability. However,
in the case of the CCK basket cell synap-
ses, the change in IPSC amplitude was
phenocopied in theNlgn3KOmouse, indi-
cating that it represents a loss-of-function
effect that is mechanistically distinct from
the one observed at PV basket cell synap-
ses of Nlgn3R451C KI mice.
It was shown previously that GABA
release at CCK basket cell synapses can
be suppressed by tonic endocannabi-
noid-mediated activation of presynaptic
CB1 receptors, most likely via constitutive
release of endocannabinoids from the
postsynaptic neuron (Katona and Freund,
2012). The authors therefore tested if the
increase in GABA release probability
observed at CCK basket cell synapses
of Nlgn3R451C KI and Nlgn3 KO mice
is caused by a deficiency in tonic endo-
cannabinoid signaling. In support of
this notion, bath application of a CB1
receptor antagonist resulted in an in-
crease in IPSC amplitudes at wild-type
synapses, but failed to further enhance
transmission at Nlgn3R451C KI or NL3
KO or R451C KI synapses, indicating
that CB1 receptor signaling was already
reduced in the two mutants. Interestingly,
Nlgn3 loss-of-function impaired tonic
endocannabinoid signaling at all CB1-
containing GABAergic synapses through-
out the hippocampus, but showed no
effect on glutamatergic transmission or
on phasic endocannabinoid signaling.
These data led the authors to conclude
that Nlgn3 is required to specifically
localize the release machinery for tonic
endocannabinoid release to CB1-con-
taining synapses.
There are several interesting lessons to
be learned from this study. First, the
observation that the same Nlgn3mutation
can have such different effects on two
types of presynapses contacting the
same postsynaptic neuron highlights410 Neuron 78, May 8, 2013 ª2013 Elsevier Ithe fundamental importance of synaptic
context in understanding Neuroligin
function. The function of Neuroligins and
Neurexins is not only diversified by ex-
tensive alternative splicing, but also by
alternate transsynaptic binding partners
such as LRRTMs or N-cadherin (reviewed
recently in Krueger et al., 2012). Accord-
ingly, each synapse type may express
its own distinct transsynaptic signaling
complex, dependent on the identity of
both the presynaptic and the postsyn-
aptic neuron. As Fo¨ldy et al. (2013) dis-
cuss, it is conceivable that the Nlgn3R451C
substitution may exert distinct effects
on the binding affinity to various transsy-
naptic partners, thereby differentially
shifting the composition of the transsy-
naptic signaling complex at PV basket
cell and CCK basket cell synapses. The
consequence of this complexity is that it
becomes challenging to predict the rele-
vance of a given mutation for ASD-related
phenotypes without directly assessing
its effects in a synapse-specific and
circuitry-specific manner. The use of
genetic strategies to selectively target
individual types of synapses, as well
as methods to elucidate the molecular
identity of transsynaptic signaling com-
plexes in a synapse-specific manner, will
be essential to fully eludicate the role of
Neuroligins in normal synapse develop-
ment and in disorders of the synapse.
A second key implication arising from
the present study is that dysregulation of
the endocannabinoid system may play
an important role in ASD pathophysio-
logy and may therefore represent a
target for pharmacological intervention.
A similar strategy was previously em-
ployed to identify the metabotropic
glutamate receptor (mGluR) signaling
pathway as a target for drug development
in several mouse models of ASD-related
disorders, including fragile X syndrome
(Bear et al., 2004), tuberous sclerosis
complex (Auerbach et al., 2011), and
Nlgn3 deletion (Baudouin et al., 2012),
and clinical trials based on these findings
are underway. Whether targeting the
endocannabinoid system in the context
of ASDs will prove to be similarly prom-
ising remains to be seen, and additional
research will be necessary to build upon
this notion. Interestingly, however, aber-
rant activation of the endocannabinoid
system was also recently reported innc.a mouse model of fragile X syndrome
(Busquets-Garcia et al., 2013; Jung
et al., 2012). Together with these findings,
the data presented by Fo¨ldy et al. indicate
that further analyses of the link between
endocannabinoid signaling and ASDs
may provide valuable insights into the
pathophysiology and potential treatment
strategies for ASDs.
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